| Literature DB >> 32670415 |
Michinobu Yoshimura1,2, Chiemi Tokushige3, Atsushi Togawa1,4, Akira Matsunaga3, Tohru Takata1,4, Yasushi Takamatsu1.
Abstract
BACKGROUND: Hypervirulent Klebsiella pneumoniae (HVKp) infections have distinct clinical manifestations from classical K. pneumoniae infections. The hallmark of HVKp infections are liver abscess formation and metastatic infections. Due to the severe sequelae of these complications, method to identify patients at-risk of HVKp infections should be developed.Entities:
Keywords: Bloodstream infection; Capsular serotype; Hypermucoviscosity; Hypervirulent Klebsiella pneumoniae; Scoring system
Year: 2020 PMID: 32670415 PMCID: PMC7346667 DOI: 10.1186/s13099-020-00374-5
Source DB: PubMed Journal: Gut Pathog ISSN: 1757-4749 Impact factor: 4.181
Clinical and bacterial characteristics of K. pneumoniae BSIs
| Characteristics | Community-onset BSIs | Hospital-onset BSIs | p value* | ||
|---|---|---|---|---|---|
| N | % | N | % | ||
| Patient demographics | |||||
| Median age, years (range) | 72.6 | 69.3–75.8 | 64.4 | 61.3–67.4 | 0.0004 |
| Male gender | 61 | 59.2 | 76 | 63.9 | 0.478 |
| Underlying disease | |||||
| Biliary tract disease | 35 | 34.0 | 17 | 14.3 | 0.0005 |
| Diabetes mellitus | 33 | 32.0 | 27 | 22.7 | 0.118 |
| Malignancy | |||||
| Hematologic | 5 | 4.9 | 19 | 16.0 | 0.008 |
| Solid organ | 43 | 41.8 | 37 | 31.1 | 0.099 |
| Other | 15 | 14.6 | 34 | 28.6 | 0.012 |
| None | 5 | 4.9 | 0 | 0 | 0.015 |
| Site of infection | |||||
| Liver abscess | 10 | 9.7 | 0 | 0 | 0.0005 |
| Biliary tract infection | 43 | 41.8 | 17 | 14.3 | < 0.0001 |
| Other intra-abdominal infection | 5 | 4.9 | 6 | 5.0 | 0.949 |
| Urinary tract infection | 20 | 19.4 | 31 | 26.1 | 0.241 |
| Pneumonia | 10 | 9.7 | 12 | 10.1 | 0.926 |
| Febrile neutropenia | 3 | 2.9 | 22 | 18.5 | 0.0003 |
| Other/unknown | 14 | 13.6 | 31 | 26.1 | 0.021 |
| Antimicrobial treatment | |||||
| Penicillins | 21 | 20.4 | 28 | 23.5 | 0.574 |
| Cephalosporins | 44 | 42.7 | 37 | 31.1 | 0.073 |
| Carbapenems | 36 | 35.0 | 49 | 41.2 | 0.341 |
| Other antimicrobials | 0 | 0 | 3 | 2.5 | 0.105 |
| None | 1 | 1.0 | 4 | 3.4 | 0.231 |
| 30-day survival (n = 213) | 79 | 82.3 | 99 | 84.6 | 0.648 |
| Bacterial phenotypes | |||||
| Capsular serotype | |||||
| K1 | 10 | 9.7 | 5 | 4.2 | 0.103 |
| K2 | 14 | 13.6 | 14 | 11.8 | 0.683 |
| Non-K1/K2 | 79 | 76.7 | 100 | 84.0 | 0.168 |
| Hypermucoviscosity | 15 | 14.6 | 6 | 5.0 | 0.016 |
| Capsule-related gene (n = 133) | |||||
| magA gene | 6/52 | 11.5 | 5/81 | 6.2 | 0.273 |
| rmpA gene | 11/52 | 21.2 | 8/81 | 6.2 | 0.010 |
| Antimicrobial resistance | |||||
| ESBL-producer | 2 | 1.9 | 22 | 18.5 | < 0.001 |
| Carbapenem resistance | 0 | 0 | 1 | 0.8 | 0.351 |
*Pearson’s χ2-test
Factors affecting the liver abscess formation
| Characteristics (N = 127) | Liver abscess (+) (N = 10) | Liver abscess (−) (N = 117) | OR, 95% CI | p value* |
|---|---|---|---|---|
| Patient demographics | ||||
| Male gender | 7 (70) | 73 (62) | 1.41, 0.35–5.72 | 0.633 |
| Age ≥ 65 years | 8 (80) | 86 (74) | 1.44, 0.29–7.16 | 0.653 |
| Community-onset BSIs | 10 (100) | 62 (53) | N/A | 0.004 |
| Underlying disease | ||||
| Biliary tract disease | 2 (20) | 29 (25) | 0.76, 0.15–3.78 | 0.735 |
| Diabetes mellitus | 3 (30) | 35 (30) | 1.00, 0.25–4.11 | 0.996 |
| Malignancy | ||||
| Hematologic | 0 (0) | 10 (9) | 0 | 0.335 |
| Solid organ | 2 (20) | 33 (28) | 0.64, 0.13–3.15 | 0.577 |
| Other | 2 (20) | 29 (25) | 0.76, 0.15–3.78 | 0.735 |
| None | 2 (20) | 3 (3) | 9.5, 1.38–65.28 | 0.007 |
| 30-day mortality (n = 120) | 3 (30) | 20 (18) | 0.68, 0.17–2.79 | 0.363 |
| Bacterial phenotypes | ||||
| Capsular serotype K1 | 5 (50) | 7 (6) | 15.71, 3.66–67.40 | < 0.0001 |
| Capsular serotype K2 | 0 (0) | 18 (16) | 0 | 0.181 |
| Hypermucoviscosity | 5 (50) | 12 (10) | 8.75, 2.21–34.64 | 0.0004 |
| ESBL-producer | 0 (0) | 8 (7) | 0 | 0.393 |
*Pearson’s χ2-test
Risk factors for liver abscess formation
| Factors | aOR, 95% CIa | p value† | Points |
|---|---|---|---|
| Community-onset BSIs | N/A | 0.0005 | 1 |
| Capsular serotype K1 | 26.47, 4.56–206.38 | 0.0003 | 1 |
| Hypermucoviscosity phenotype | 9.59, 1.77–51.20 | 0.010 | 1 |
†Pearson’s χ2-test
aAdjusted by age, sex, and underlying diseases
Fig. 1Receiver operator characteristic curve analysis for the scoring system
Accuracy of the proposed scoring system for the diagnosis of HV K. pneumoniae infection
| Score | Liver abscess (+) | Liver abscess (−) | Sensitivity | Specificity | Youden’s index (J) |
|---|---|---|---|---|---|
| ≥ 0 | 10 | 212 | 1 | 0 | 0 |
| ≥ 1 | 10 | 101 | 1 | 0.52 | 0.52 |
| ≥ 2 | 7 | 12 | 0.70 | 0.94 | 0.64 |
| 3 | 3 | 3 | 0.30 | 0.99 | 0.29 |
| Number in sample | 10 | 212 |